Despite their efficacy in the treatment of benign prostatic hyperplasia, the popularity of inhibitors of 5a-reductase (5ARIs) is limited by their association with adverse sexual side effects. The aim of this study was to review and meta-analyze currently available randomized clinical trials evaluating the rate of sexual side effects in men treated with 5ARIs. An extensive Medline Embase and Cochrane search was performed including the following words: 'finasteride', 'dutasteride', 'benign prostatic hyperplasia'. Only placebo-controlled randomized clinical trials evaluating the effect of 5ARI in subjects with benign prostatic hyperplasia were considered. Of 383 retrieved articles, 17 were included in this study. Randomized clinical trials enrolled 24,463 in the active and 22,270 patients in the placebo arms, respectively, with a mean follow-up of 99 weeks and mean age of 64.0 years. No difference was observed between trials using finasteride or dutasteride as the active arm considering age, trial duration, prostate volume or International Prostatic Symptoms Score at enrollment. Overall, 5ARIs determined an increased risk of hypoactive sexual desire [OR = 1.54 (1.29; 1.82); p < 0.0001] and erectile dysfunction [OR = 1.47 (1.29; 1.68); p < 0.0001]. No difference between finasteride and dutasteride regarding the risk of hypoactive sexual desire and erectile dysfunction was observed. Meta-regression analysis showed that the risk of hypoactive sexual desire and erectile dysfunction was higher in subjects with lower Q max at enrollment and decreased as a function of trial follow-up. Conversely, no effect of age, low urinary tract symptom or prostate volume at enrollment as well as Q max at end-point was observed. In conclusion, present data show that the use of 5ARI significantly increases the risk of erectile dysfunction and hypoactive sexual desire in subjects with benign prostatic hyperplasia. Patients should be adequately informed before 5ARIs are prescribed.
INTRODUCTION
Benign prostatic hyperplasia (BPH) is a frequent condition of the aging male, with a histological prevalence at autopsy of 50% in men aged 50-60 years and of 90% over 80 years (McVary, 2006) . BPH is mainly a histological diagnosis, the clinical counterparts of which are benign prostate enlargement, and benign prostate obstruction (Abrams, 1999) . The two clinical entities are characterized by a progressive development of symptoms (lower urinary tract symptoms, LUTS) -that are only partially derived from the prostate enlargement -which can affect quality of life and sexual function (Corona et al., 2014a; Gacci et al., 2014 Gacci et al., , 2015 Vignozzi et al., 2014; F€ ullhase & Hakenberg, 2015) . BPHassociated LUTS are probably the most common urological conditions of aging men, with an estimated overall prevalence of 10.3%, and an overall incidence rate of 15 per 1000 males per year with even higher rates in older individuals (Verhamme et al., 2002) . Medical treatment is mainly based on the use of alpha-blockers and 5-alpha reductase inhibitors (5ARIs; F€ ullhase & Hakenberg, 2015; Yuan et al., 2015) . More recently, phosphodiesterase type 5 inhibitors (PDE5i), and tadalafil in particular, have been demonstrated to improve LUTS/BPH, although their role in reducing obstructive symptoms is more conflicting (Gacci et al., 2012) . A large body of evidence has documented that alpha-blockers and 5ARIs can improve not only LUTS but also urinary flow (F€ ullhase & Hakenberg, 2015; Yuan et al., 2015) . However, the use of these medications has often been associated with a further worsening of sexual function. Alpha-blockers can induce retrograde ejaculation . Similarly, ejaculatory problems might be associated also with the use of 5ARIs . In addition, in the last few years there has been a rising concern about the possibility that 5ARIs can lead to erectile dysfunction (ED) and hypoactive sexual desire (HSD) in subjects with BPH, which can persist even after drug withdrawal (Traish et al., 2011; Corona et al., 2012a; Gur et al., 2013) . Similar data have been reported for the use of finasteride for the treatment of adrogenetic alopecia (Belknap et al., 2015) . In line with this evidence, the Food and Drug Administration in 2011 and 2012 announced finasteride labeling changes, including a list of reported sexual adverse events (http://www.fda.gov/Drugs/Drug Safety/InformationbyDrugClass/ucm299754.htm).
The specific mechanisms underlining the negative effects of 5ARIs on sexual function remain to be elucidated. In addition, although some studies reported a high incidence of sexual dysfunction in men treated with 5ARIs compared with placebo (Nickel et al., 1996) , others did not confirm it (Roehrborn et al., 2002) . A recent network meta-analysis of available evidence, performed by Yuan et al. (2015) , documented that 5ARIs are associated with a higher risk of adverse events, when compared with placebo; however, no specific information on sexual side effects was provided. In addition, a recent meta-analysis evaluating the rate of sexual adverse events in men treated with a low dose of finasteride (1 mg daily) for androgenic alopecia reported that available data are too limited and of poor quality and therefore insufficient for establishing safety (Belknap et al., 2015) .
The aim of this study was to perform a systematic review and meta-analysis of all randomized-controlled trials (RCTs), placebo controlled, evaluating the rate of sexual side effects in men treated with 5ARIs.
METHODS
This meta-analysis was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline (see Appendix S1) (http://www. prisma-statement.org/).
An The search, which accrued data from January 1, 1969 up to May 1st 2016, was restricted to placebo-controlled RCTs and humans. In addition, completed but still unpublished RCTs were identified through a search at www.clinicaltrials.gov website. The identification of relevant studies was performed independently by two of the authors (D.S., G.C.) and conflicts resolved by the third investigator (M.M.). We did not employ search software. We hand-searched bibliographies of retrieved papers for additional references. The principal source of information was derived from published articles; if data were missing from the publication, an attempt at retrieval was made through the clinicaltrial.gov website.
Study selection
We included only placebo-controlled RCTs, comparing the effect of finasteride and dutasteride on BPH (see also Fig. 1 and Table 1 ). Studies evaluating the effect of finasteride on hair loss were excluded from the analysis (Fig. 1) . In addition, as phosphodiesterase type 5 inhibitors (PDE5i) have a positive influence on sexual function, trials evaluating the effect of PDE5i as an add-on to 5ARIs were excluded from the analysis (Casab e et al., 2014; Glina et al., 2015; Roehrborn et al., 2015 , see also Fig. 1) . Similarly studies evaluating the combination therapy of 5ARIs plus a blockers for BPH were not included. Editorials, letters to the editor, review articles, commentary, meeting abstracts, case reports and animal experimental studies were excluded (Fig. 1) .
Outcome
The principal outcome of this analysis was the effect of 5ARIs as compared with placebo on sexual function and in particular on ED and sexual desire. HSD and ED were defined as reduced libido and erectile difficulties, as reported, as the treatment of emergent adverse events. Possible factors underlying 5ARI-related sexual dysfunction were evaluated by performing metaregression analyses (see below).
Quality assessment
The quality of trials was assessed using the Cochrane criteria (www.cochrane-handbook.org; see also Table 1 ). In particular, the following criteria were evaluated: how the randomization sequence was generated, how allocation was concealed, whether there were important imbalances at baseline, which groups were blinded (patients, caregivers, data collectors, outcome assessors, data analysts), what the loss to follow-up rate was (in the intervention and the control arm), whether the analyses were by intention to treat, and how missing outcome data were dealt with. For each study, we also assessed how the population was selected, and the adequacy of study follow-up (Table 1) .
Statistical analysis
Heterogeneity was assessed by using I 2 statistics. However, a random-effects model was applied to all analyses, even when low heterogeneity was detected, because the validity of tests of heterogeneity can be limited with a small number of component studies. To estimate possible publication or disclosure bias, we used funnel plots and the Begg-adjusted rank correlation test (Begg & Mazumdar, 1994; Egger et al., 1997) . However, because these tests have low statistical power when the number of trials is small, undetected bias may still be present. Meta-regression analyses were carried out to test the effects of several factors on 5ARI-induced ED and HSD. Specific sensitivity analyses were also performed to evaluate the independent effect of finasteride and dutasteriude on sexual function. Multivariate linear regression analysis model, weighting each study for the number of subjects enrolled, was performed to verify the effect of several factors on 5ARI-induced sexual dysfunction. All analyses were performed using COMPREHENSIVE META-ANALYSIS Version 2; Biostat (Englewood, NJ, USA). Multivariate analyses were performed on SPSS (Statistical Package for the Social Sciences; Chicago, IL, USA) for Windows 22.0.
RESULTS
Out of 383 retrieved articles, 17 were included in the study. In particular, 12 compared finasteride and four dutasteride vs. placebo, respectively (Table 1 ). In addition, in one study both finasteride and dutasteride were compared with placebo (Table 1) . The trial flow is summarized in Figure S1 . Available RCTs enrolled 24,463 subjects in the active and 22,270 patients in the placebo arms, respectively, with a mean follow-up of 99.0 weeks and mean age of 64.0 years. No difference between trials with finasteride and dutasteride was observed with respect to age, trial duration, prostate volume or LUTS score at enrollment (63.9 AE 1.4 vs. 64.3 AE 2.2 years, 104.5 AE 105.6 vs. 84.8 AE 80.9 months, 44.3 AE 8.1 vs. 44.1 AE 2.0 mL, 15.2 AE 3.6 vs. 15.0 AE 4.3 LUTS score for finasteride and dutasteride, respectively; all p = NS). Sexual function and LUTS were investigated with different tools. The characteristics of the trials included in the metaanalysis are summarized in Table 1 .
Libido
Among the selected studies, 15 provided information on libido. I 2 was 26.7, p = 0.15. Overall, 5ARIs lead to an increased risk of HSD [OR = 1.54 (1.30; 1.81); p < 0.0001] (see also Fig. 2) . Similar results were observed by performing a sensitivity analysis considering the effect of finasteride or dutasteride alone vs. placebo (see Fig. 2 and Figure S1 , panel A and B). No difference between finasteride and dutasteride on the risk of HSD was observed (Q = 0.05; p = 0.83). Funnel plot and Begg-adjusted rank correlation test suggested publication bias (Kendall's s: 0.43; p = 0.02), however, the increased risk of 5ARIs-related HSD was confirmed by applying Duval and Tweedie's 'trim and fill' method [OR = 1.38 (1.14; 1.66)].
Meta-regression analysis showed that the risk of HSD decreased as a function of treatment duration and it was higher in trials enrolling subjects with lower mean Q max [S = À0.001 (À0.002; À0.001), p = 0.002; I = 0.685 (0.417; 0.9534), p < 0.0001 and S = À0.642 (À1.288; À0.005), p = 0.05; I = 7.375 (0.350; 14.399), p = 0.04 for duration of treatment and Q max , respectively] (see also Figure S2 , Panel A and B). The negative association between HSD risk and Q max at enrollment or trial duration was confirmed in a 
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Dutasteride N 4 Figure 1 Trial flow diagram. Unpublished studies were identified through a search of www.clinicaltrials.gov website. N, number; BPH, benign prostatic hyperplasia; PDE5i, phosphodiesterase inhibitors; 5ARI, inhibitors of 5a-reductase. 674 Andrology, 2017, 5, 671-678 multivariate analysis after adjustment for age (Adj.r = À0.060 and À0.483, respectively; both p < 0.001). Conversely, no effect of age, International Prostatic Symptoms Score (IPSS) score, prostate volume at enrollment, or Q max at end-point was observed (not shown).
Erectile dysfunction
Information on ED was available in all included trials. I 2 was 28.94, p = 0.12. Funnel plot and Begg-adjusted rank correlation test suggested no major publication bias (Kendall's s: À0.04; p = 0.82). Overall, 5ARIs were associated with an increased risk of ED [s OR = 1.47 (1.29; 1.68); p < 0.0001] (see also Fig. 2 ). Similar results were observed by performing a sensitivity analysis considering the specific effect of finasteride or dutasteride vs. placebo ( Fig. 2 and Figure S1 , panel C and D). No difference between finasteride and dutasteride in the risk of ED was observed (Q = 0.68; p = 0.41). Similar to what was observed for libido, meta-regression analysis showed that the risk of ED decreased as a function of trial duration [S = À0.001 (À0.002; À0.001); p = 0.002 and I = 0.617 (0.403; 0.830); p < 0.0001] (see also Figure S2 , Panel C). Conversely, no association between Q max at enrollment and ED risk was observed when the entire population was considered (not shown). However, an inverse association between ED and Q max was observed when studies enrolling subjects with severe urinary flow impairment at enrolment (Q max at enrollment < 9 cm/sec) were excluded from the analysis [S = À0.667 (À1.287; À0.047); p = 0.03 and I = 7.589 (0.834; 14.345); p = 0.03] (see also Figure S2 , Panel D). The negative association between ED risk and trial follow-up or Q max at enrollment (after excluding patients with severe Q max impairment) was confirmed in a multivariate analysis after adjustment for age (Adj.r = À0.302 and À0.701, respectively; both p < 0.0001). Conversely, similar to what was observed for HSD, no effect of age, IPSS score, prostate volume at enrollment and Q max at end-point was observed (not shown).
DISCUSSION
In this study, by applying a meta-analytic method, we show that the use of 5ARIs in men with BPH is associated with an increased risk of ED and HSD, when compared with placebo. No difference between finasteride and dutasteride was observed. Similar results were previously reported for ejaculatory problems . In addition, our data show that the negative effects of 5ARIs on sexual function were inversely related to study duration and that they were higher in subjects with a lower urinary flow at enrollment.
A large body of evidence has documented that androgens are essential for male sexual function (Corona et al., 2012b (Corona et al., ,c, 2016 Isidori et al., 2015) . Accordingly, the use of testosterone (T) substitution (TS) in hypogonadal men (total T < 12 nmol/L) is able to improve all aspects of sexuality, including erectile function and sexual desire (Corona et al., 2014b (Corona et al., , 2016 .
Androgens also play a crucial role in regulating prostate growth and prostate cell differentiation (Corona et al., 2011 (Corona et al., , 2012d . Wilson (1972) first hypothesized that the main androgen inducing prostate growth was not T per se but its conversion to dihydrotestosterone (DHT). Accordingly, 5ARIs are an effective treatment for BPH, decreasing DHT levels by 60%, with a consequent T increase of about 15% (Imperato- Figure 2 Odds ratio (95% CI) for reduced libido or erectile dysfunction of finasteride 5 mg or dutasteride 0.5 mg over placebo.
© 2017 American Society of Andrology and European Academy of Andrology Andrology, 2017, 5, 671-678 675 5a-REDUCTASE INHIBITORS AND SEXUAL DYSFUNCTIONSFUNCTION 2012a). In fact, subjects with congenital 5a-reductase type 2 deficiency (a rare genetic disorder characterized by a reduced conversion of T into DHT), after puberty, often have normal sexual desire (Brinkmann et al., 2007) . Similarly, the CHAMP study, a population-based survey including more than 1700 men aged 70 years and older, did not report any association between mass-derived DHT and sexual desire (Hsu et al., 2015) . An alternative working hypothesis is that a 5a-reductase blockage within the brain could impair formation of other 5a-reduced steroid metabolites, which, acting as neurosteroids (Gur et al., 2013) , can regulate sexual desire. Accordingly, 20-day finasteride treatment in rats was able to alter neuroactive steroid levels, as well as steroid and GABA-A receptors within specific areas of the brain (Giatti et al., 2015) . Similar considerations can be drawn for the relationship between DHT and the incidence of ED. DHT is the most potent androgen involved in genital tissue development. However, no major differences could be found when comparing the in vitro effects of T and DHT on erectile function (Isidori et al., 2014; Corona et al., 2016) . Pinsky et al. (2011) documented that, in rats, dutasteride has a detrimental effect on erectile function, reducing relaxation of corpora cavernosa strips -induced by electrical field stimulation or acetylcholine -and the erectile response to stimulation of the cavernous nerve. The same authors also reported that dutasteride increased collagen deposition and altered expression of neuronal NOS and inducible NOS. Similar results have been previously reported with finasteride (Lugg et al., 1995) . Overall, animal models show that 5ARIs induce structural and functional alterations in penile tissue contributing to penile fibrosis that is mainly exerted through a modulation of cholinergic and nitrergic sensitivity, with no apparent change in PDE5 (Gur et al., 2013) . Hence, a drug-related, DHT-mediated effect has been hypothesized to explain the relationship between 5ARI treatment and ED. This hypothesis needs to be confirmed in humans. Interestingly, our data show that the risk of 5ARI-related sexual dysfunction is higher in subjects with a higher impairment of urinary flow at enrollment, although no relationship with IPSS score was documented. In line with our data, Morant et al. (2009) previously reported that obstructive rather than voiding symptoms were the best predictors of ED in men with BPH. Unfortunately, the available information on IPSS subscales was insufficient to test the contribution of storage IPSS score on 5ARIs-induced sexual dysfunction in our study. The pathogenetic mechanism linking LUTS/BPH and ED have not been completely clarified. Common alterations in the nitric oxide-cyclic guanosine monophosfate pathway, enhancement of RhoARho-kinase signaling and pelvic atherosclerosis are often considered as the most important mechanisms involved in determining the two conditions (Corona et al., 2014a; Gacci et al., 2016) . It could be speculated that a background characterized by impaired NO signaling and hyperactivation of RhoA/Rho kinase makes subjects with LUTS more susceptible to adverse effects of 5ARIs on erectile function.
The association between 5ARI-induced HSD and urinary obstruction is even more problematic to clarify. However, it should be recognized that LUTS/BPH can negatively affect quality of life and mood, which can eventually explain the relationship with impaired sexual desire (Castellini et al., 2016) . It should also be considered that the impairment of sexual desire could be, at least partially, the consequence of 5ARI-induced ED (Corona et al., 2013) .
The negative association between trial duration and 5ARI-associated sexual dysfunction is not surprising. Several authors have documented that ED occurs predominantly during the first year of 5ARI therapy, with a complete remission in half of the patients after 12 months and with further improvement with continuation of therapy (Stoner, 1994; Wessels et al., 2003; Moinpour et al., 2007) . Similar results have been reported by other authors (Thompson et al., 2003; Wessels et al., 2003) . The reasons underlying this finding are not known, but it is important to recognize that ED because of finasteride has also been related to the nocebo effect, i.e. an adverse effect that is not a direct result of the specific pharmacological action of the drug (Mondaini et al., 2007) . On the other hand, it could be speculated that the compensatory increase in sex hormone binding globuline (SHBG)-bound and -unbound T observed during the use of 5ARIs might mitigate the fall of DHT over time (Corona et al., 2014a,b) .
Several limitations should be recognized. Sexual function and LUTS were evaluated with different tools. No information on sexual function after 5ARI withdrawal was available. Meta-analyses are based on the synthetic reports of averaged results obtained in each study, without access to patient-level data. For this reason, some of the original information of each study is lost in meta-analyses. On the other hand, the possibility of combining a large number of investigations allows for a much greater statistical power, limiting the chance of casual results, because of small sample size. It is also possible that some of the results reported here were caused by the effects of unadjusted confounders. Hence, great caution is required in the interpretation of these results, which should be confirmed in large-scale observational studies.
In conclusion, the present data show that the use of 5ARIs significantly increases the risk of erectile dysfunction and hypoactive sexual desire in subjects with benign prostatic hyperplasia particularly when obstructive symptoms are present. Even though some of the sexual adverse events tend to disappear after a few months of therapy, in the vast majority of cases, patients should be adequately informed before 5ARIs are prescribed.
